Sector
PharmaceuticalsOpen
₹3,368.85Prev. Close
₹3,361.5Turnover(Lac.)
₹9,958.93Day's High
₹3,375.9Day's Low
₹3,30252 Week's High
₹3,590.752 Week's Low
₹2,025.7Book Value
₹229.23Face Value
₹5Mkt Cap (₹ Cr.)
1,12,915.56P/E
69.57EPS
48.34Divi. Yield
0.83Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 169.23 | 169.23 | 84.62 | 84.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6,659.53 | 6,286.73 | 6,260.8 | 5,945.48 |
Net Worth | 6,828.76 | 6,455.96 | 6,345.42 | 6,030.1 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 6,742.32 | 6,450.57 | 6,168.44 | 4,248.24 |
yoy growth (%) | 4.52 | 4.57 | 45.19 | -7.49 |
Raw materials | -1,907.5 | -1,669.67 | -1,637.45 | -1,115.69 |
As % of sales | 28.29 | 25.88 | 26.54 | 26.26 |
Employee costs | -1,097.93 | -1,097.12 | -1,061.76 | -826.07 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,466.21 | 1,366.11 | 1,116.77 | 562.13 |
Depreciation | -602.43 | -609.84 | -606.66 | -383.88 |
Tax paid | -474.76 | -228.26 | -178.26 | -80.09 |
Working capital | -48.68 | 274.86 | 692.18 | 68.94 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.52 | 4.57 | 45.19 | -7.49 |
Op profit growth | -4.15 | 14.33 | 111.26 | -19.49 |
EBIT growth | 0.13 | 9.88 | 80.79 | -26.05 |
Net profit growth | -12.86 | 21.24 | 94.69 | -43.56 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 10,562 | 9,464 | 8,419 | 7,886 | 7,780 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 10,562 | 9,464 | 8,419 | 7,886 | 7,780 |
Other Operating Income | 166 | 156 | 89 | 119 | 159 |
Other Income | 146 | 45 | 197 | 57 | 122 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,813.45 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,096.2 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,498.25 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,361.5 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,615.5 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman Emeritus
Sudhir Mehta
Executive Chairman
Samir Mehta
Independent Director
Ameera Shah
Independent Director
Nayantara Bali
Director (Operation)
Jinesh Shah
Independent Director
Maurice Chagnaud
Whole Time Director
Aman Mehta
Independent Director
Manish Choksi
Company Sec. & Compli. Officer
Chintan Trivedi
Independent Director
Nikhil Khattau
Non Executive Director
Jindal Mehta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Torrent Pharmaceuticals Ltd
Summary
Torrent Pharmaceuticals Limited, the flagship Company of the Torrent Group, is one of the leading pharmaceutical companies having presence in Indian and global markets. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Brazil and Rest of the World. The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil. Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million.Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public in July 15th, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in year 1983. In year 1986, it started second manufacturing plant at Chhatral. In the year 1995, Torrent Gujarat Biotech Ltd plant was commissioned.In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the
Read More
The Torrent Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹3336.45 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Torrent Pharmaceuticals Ltd is ₹112915.56 Cr. as of 06 Dec ‘24
The PE and PB ratios of Torrent Pharmaceuticals Ltd is 69.57 and 15.12 as of 06 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Torrent Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Torrent Pharmaceuticals Ltd is ₹2025.7 and ₹3590.7 as of 06 Dec ‘24
Torrent Pharmaceuticals Ltd's CAGR for 5 Years at 29.11%, 3 Years at 31.79%, 1 Year at 60.07%, 6 Month at 20.90%, 3 Month at -2.35% and 1 Month at 5.57%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice